Source comparison
Best Tesamorelin Dosage for Lipodystrophy: Comparison of Clinical Protocols
| Protocol | Dose | Frequency | Duration Studied | VAT Reduction (vs Baseline) | Glucose Impact | Clinical Context ||—|—|—|—|—|—|| FDA-Approved (Egrifta) | 2mg SC | Daily | 26–52 weeks | −15.2% at 26 weeks | Modest HbA1c increase (+0.2–0.4%) in glucose-normal
This comparison does not assign a generated winner or score.
- | Protocol | Dose | Frequency | Duration Studied | VAT Reduction (vs Baseline) | Glucose Impact | Clinical Context ||—|—|—|—|—|—|| FDA-Approved (Egrifta) | 2mg SC | Daily | 26–52 weeks | −15.2% at 26 weeks | Modest HbA1c increase (+0.2–0.4%) in glucose-normal patients; contraindicated in active diabetes | Only protocol with Phase III evidence; approved specifically for HIV-associated lipodystrophy || Off-Label Lower Dose | 1mg SC | Daily | Limited data | Approximately −8% (Phase II estimates) | Minimal | Investigated in dose-ranging studies but not pursued due to inferior efficacy || Off-Label Higher Dose | 3mg SC | Daily | Limited data | Marginal additional VAT loss vs 2mg | Increased glucose dysregulation and IGF-1 elevation | Phase II data showed diminishing returns with safety concerns || Intermittent Dosing (Speculative) | 2mg SC | 3–5 days/week | No published data | Unknown | Unknown | Theoretical approach to reduce cost or side effects. No clinical validation || Professional Ass